

# Pharmaxis Ltd

14:57 22 Feb 2019

## Pharmaxis begins phase one clinical trial of compound targeting pancreatic cancer

Pharmaxis Ltd (ASX:PXS) has begun dosing of the first subject in its phase-one clinical trial of an anti-fibrotic Lysyl Oxidase (LOX) inhibitor, focused on treating cancer.

The program compound is an oral once-a-day drug that inhibits all members from the lysyl oxidase enzyme family.

The company successfully cleared pre-clinical safety and toxicity studies in the third quarter of 2018 and has shown significant reductions in in-vivo models of kidney and lung fibrosis, as well as myelofibrosis and pancreatic cancer.

### New approach for stromal tumour treatment

Pharmaxis chief executive officer Gary Phillips said: "Moving a new drug into the clinic for the first time is always a significant milestone and this will be the fourth time we have accomplished this during the last 5 years.

"I'm delighted with the productivity of the Pharmaxis team and excited about the potential of this drug to bring a new approach to therapy for hard to treat stromal tumours like pancreatic cancer.

"Our current plan is that a successful phase 1 trial outcome would be the launch pad for a quick transition into cancer patients and to that end we are already in discussion with key leaders and working on potential trial designs."

### READ: Pharmaxis well-funded as potential partners assess its anti-fibrotic mechanisms

The double-blind placebo-controlled study consists of two stages.

The first single ascending dose will be conducted in 40 healthy subjects divided into five groups with each subject taking a single dose or placebo.

The second multiple ascending dose stage will be conducted in 16 healthy subjects and divided into two groups, with each group receiving a different dose or placebo for seven days.


### READ: Pharmaxis LOXL2 program phase 2 ready after completion of 13-week toxicity studies

The company received reports on the 13-week toxicity studies in January 2019 which were conducted for each of its two Lysyl Oxidase Like 2 (LOXL2) inhibitors.

**Price:** 0.265

**Market Cap:** \$104.59 m

### 1 Year Share Price Graph



### Share Information

**Code:** PXS

**Listing:** ASX

**52 week High Low**  
0.305 0.18

**Sector:** Pharma & Biotech

**Website:** www.pharmaxis.com.au

### Company Synopsis:

*Pharmaxis Ltd (ASX:PXS) is a specialty pharmaceutical company focused on the development of new products for the diagnosis and treatment of chronic respiratory and immune disorders.*

action@proactiveinvestors.com.au

Both were drug compounds were tested at a range of doses in two species over the 13-week period to establish the No Observed Adverse Effect Level (NOAEL).

Doses that resulted in 85% or greater inhibition of the target enzyme in the phase 1 studies were below the human equivalent NOAEL doses and therefore an adequate safety margin to start phase 2 studies up to three months.

The Australian pharmaceutical research company is focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval. Its product Bronchitol for cystic fibrosis is marketed in Europe, Russia and Australia and its product Aridol, for the assessment of asthma is sold in the US, Europe, Australia and Asia.

Its product Bronchitol for cystic fibrosis is marketed in Europe, Russia and Australia and its product Aridol, for the assessment of asthma is sold in the US, Europe, Australia and Asia.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

#### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).